EDWARDS LIFESCIENCES CORPORATION (EW) FY2026 YTD Q2 P&L / Income Statement

EDWARDS LIFESCIENCES CORPORATION (EW) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

3,389,600,000 US dollars

Cost of sales

755,000,000 US dollars

Gross profit

2,634,600,000 US dollars

Operating costs, net of other operating income (calculated)

1,643,800,000 US dollars

Operating income, net

990,800,000 US dollars

Other income (expense), net (calculated)

negative 12,000,000 US dollars

Income from continuing operations before provision for income taxes

978,800,000 US dollars

Provision for income taxes

356,700,000 US dollars

Net income

622,100,000 US dollars

Transcatheter Aortic Valve Replacement

2,455,600,000 US dollars

Transcatheter Mitral and Tricuspid Therapies

373,700,000 US dollars

Surgical

560,300,000 US dollars

Selling, general, and administrative expenses

1,083,400,000 US dollars

Research and development expenses

542,200,000 US dollars

Certain litigation expenses

43,400,000 US dollars

Separation costs

0 US dollars

Other operating income

negative 25,200,000 US dollars

Loss from discontinued operations, net of tax

0 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
• Of which attributable to EDWARDS LIFESCIENCES CORPORATION: $622.60 M; to noncontrolling interests: −$500.00 K.